Sakura Finetek Europe and MEDIPATH, a group of independent French pathologists, announced their collaboration to enhance cancer diagnostics and thus contribute to improved patient therapeutic management. As part of this initiative, MEDIPATH deployed four of Sakura’s Tissue-Tek AutoTEC® a120s for automated embedding in their pathology centres in Fréjus, Paris, Eguilles (Aix-en-Provence) and Montpellier. This decision is part of an ongoing commitment to improving the quality of care provided to patients and in response to the significant increase in cancer cases over the last years.

Sample pre-analytical treatment, from collection to slide preparation, is a complex process crucial for diagnostic accuracy. Implementing these innovative instruments will allow MEDIPATH to standardise embedding while ensuring timely report delivery in line with its quality charter.

“MEDIPATH is a major player in cancer screening in France, processing over 1.5 million cases each year, including 140,000 cancer diagnoses, with these numbers steadily increasing,” said Olivier Vire, President of MEDIPATH. “We are convinced that this technological advancement will not only strengthen our commitment to medical excellence but will also meet the growing expectations of our patients for quality care and timely results.”

Each pathology centre has unique goals. Sakura's technology, employees, expertise, and services enable each client to achieve these optimally. Mateo Iglesias, Vice President of Marketing, Strategy, and Innovation at Sakura Finetek Europe, commented: “As part of our Bridge service offering, our implementation specialists worked closely with MEDIPATH’s technical teams to analyse existing workflows, implement lean management practices, train technicians, and maximise system utilisation.”

The Tissue-Tek AutoTEC a120 from Sakura is the industry's first and only fully automated embedding system. By combining this instrument with Tissue-Tek® Paraform® embedding cassettes and gels, pathology centres have a complete system for automating cassette embedding, with a maximum throughput of 120 cassettes per hour. The machine’s consistent handling allows for optimal repeatability. Samples do not leave their original cassette, meaning they retain their case number to ensure identity vigilance. This also allows for quicker comprehensive sample imaging and traceability throughout the embedding process.

Please click here for more information about the Tissue-Tek AutoTEC a120 and our product brochure.

About MEDIPATH

Founded in 1999, MEDIPATH comprises over 120 independent pathologists (including 12 reference pathologists in national networks for rare pathology expertise from the National Cancer Institute and 10 molecular pathologists) and more than 700 employees across 33 locations. Led by its associate physicians, the group pursues a public health mission in cancer screening and diagnosis, collaborating with over 250 healthcare facilities and processing over 1.5 million cases yearly, including 140,000 cancer diagnoses. Its technical platforms' excellence, active commitment to innovation, and geographical network enable MEDIPATH to successfully pursue its primary goal: "a shared access to excellence, with local expertise in patient management."

About Sakura Finetek Europe

Sakura Finetek Europe is a leading provider of advanced technologies and solutions in anatomical pathology. With a commitment to innovation and excellence, Sakura Finetek Europe empowers healthcare professionals worldwide to deliver accurate diagnoses and improve patient outcomes.